The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists

General Hospital Psychiatry

Volumn 31, Issue 5, 2009, Pages 403-413

  Yonkers, Kimberly A ^a   Wisner, Katherine L ^b   Stewart, Donna E ^c   Oberlander, Tim F ^d   Dell, Diana L ^e   Stotland, Nada ^f   Ramin, Susan ^g   Chaudron, Linda ^h   Lockwood, Charles ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f RUSH MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Antidepressant agents; Depression; Pregnancy

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; DULOXETINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ALGORITHM; ANTICHOLINERGIC SYNDROME; ARTICLE; COGNITIVE DEFECT; COGNITIVE THERAPY; CONGENITAL HEART MALFORMATION; CONSTIPATION; CONSULTATION; DEPRESSION; DRUG OVERDOSE; ELECTROCONVULSIVE THERAPY; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; HUMAN; IRRITABILITY; MAJOR DEPRESSION; MEDLINE; MOOD DISORDER; PERINATAL PERIOD; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PROGENY; PSYCHOTHERAPY; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS; RISK ASSESSMENT; SEDATION; SIDE EFFECT; SPONTANEOUS ABORTION; SYMPTOM; TERATOGENICITY; TOBACCO DEPENDENCE; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; DEPRESSION; FEMALE; FETAL DEVELOPMENT; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 69049099828     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2009.04.003     Document Type: Article

References (64)

1. Gaynes B.N., et al. Perinatal depression: prevalence, screening accuracy and screening outcomes. Evid. Rep./Technol. Assess. (Summ.) (2005) 1-8
2. Cooper W.O., Pont M.E., and Ray W.A. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 196 (2007) 544.e1
3. Kitamura T., Shima S., Sugawara M., and Toda M.A. Psychological and social correlates of the onset of affective disorders among pregnant women. Psychol Med 23 (1993) 967-975
4. Swallow B.L., Lindow S.W., Masson E.A., and Hay D.M. Psychological health in early pregnancy: relationship with nausea and vomiting. J Obstet Gynaecol 24 (2004) 28-32
5. Sugiura-Ogasawara M., et al. Depression as a potential causal factor in subsequent miscarriage in recurrent spontaneous aborters. Hum Reprod 17 (2002) 2580-2584
6. Nakano Y., et al. Psychosocial predictors of successful delivery after unexplained recurrent spontaneous abortions: a cohort study. Acta Psychiatr Scand 109 (2004) 440-446
7. Nelson B.A., McMahon K., Joffe M., and Brensinger C. The effect of depressive symptoms and optimism on the risk of spontaneous abortion among innercity women. J Womens Health 12 (2003) 569-576
8. Steer R.A., Scholl T.O., Hediger M.L., and Fischer R.L. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 45 10 (1992) 1093-1099
9. Oberlander T., Warburton W., Misri S., Aghajanian J., and Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 63 (2006) 898-906
10. Andersson L., Sundstrom-Poromaa I., Wulff M., Astrom M., and Bixo M. Neonatal outcome following maternal antenatal depression and anxiety: a population-based study. Am J Epidemiol 159 (2004) 872-881
11. Suri R., et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 164 (2007) 1206-1213
12. Orr S., James S., and Blackmore Prince C. Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, MD. Am J Epidemiol 156 (2002) 797-802
13. Field T., Diego M., and Hernandez-Reif M. Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev 29 (2006) 445-455
14. DiPietro J., et al. Maternal psychological distress during pregnancy in relation to child development at age two. Child Dev 77 (2006) 573-587
15. Punamaki R. Maternal mental health and medical predictors of infant developmental and health problems from pregnancy to one year: does former infertility matter?. Infant Behavior & Development 29 (2006) 230-242
16. Deave T., Heron J., Evans J., and Emond A. The impact of maternal depression in pregnancy on early child development. BJOG 115 (2008) 1043-1051
17. Headley J., Northstone K., Simmons H., Golding J., and ALSPAC Study Team. Medication use during pregnancy: data from the Avon Longitudinal Study of Parents and Children. Eur J Clin Pharmacol 60 (2004) 355-361
18. Källén B.A., and Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 79 (2007) 301-308
19. Chambers C.D., Johnson K.A., Dick L.M., and Felix R.J. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 335 (1996) 1010-1015
20. Chun-Fai-Chan B., et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 192 (2005) 932-936
21. Einarson A. Pregnancy outcome following gestational exposure to venlafaxine: A multicenter prospective controlled study. Am J Psychiatry (2001) 158
22. Einarson A., et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry 48 (2003) 106-110
23. Kulin N., et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA 279 8 (1998) 609-610
24. Pastuszak A., et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 269 17 (1993) 2246-2248
25. Hemels M., Einarson A., Koren G., Lanctot K., and Einarson T. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother 39 (2005) 803-809
26. Saraiya M., Berg C., Shulman H., Green C., and Atrash H. Estimates of the Annual Number of Clinically Recognized Pregnancies in the United States, 1981-1991. Am J Epidemiol 149 (1999) 1025-1029
27. Simon G., Cunningham M., and Davis R. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 159 (2002) 2055-2061
28. Wen S., et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. J Obstet Gynecol 194 (2006) 961
29. Djulus J., et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 67 (2006) 1280-1284
30. Sivojelezova A., Shuhaiber S., Sarkissian L., Einarson A., and Koren G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. J Obstet Gynecol 193 (2005) 2004
31. Malm H., Klaukka T., and Neuvonen P. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 106 (2005) 1289-1296
32. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. [see comment]. Arch Pediatr Adolesc Med 158 (2004) 312-316
33. Oberlander T., Warburton W., Misri S., Aghajanian J., and Hertzman C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitors: population based study. Br J Psychiatry 192 (2008) 338-343
34. Hamilton B., Martin J., and Ventura S. Births: preliminary data for 2005. National vital statistics report. National Center for Health Statistics (2007)
35. Costei A., Kozer E., Ho T., Ito S., and Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 156 (2002) 1129-1132
36. Altshuler L., et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. [see comments]. Am J Psychiatry 153 (1996) 592-606
37. Louik C., Lin A., Werler M., Hernandez-Diaz S., and Mitchell A. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 356 (2007) 2675-2683
38. Alwan S., et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 356 (2007) 2684-2692
39. Kallen B., and Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 21 (2006) 221
40. Cole J., et al. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16 (2007) 474-484
41. Einarson A., et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 165 (2008) 749-752
42. Oberlander T.F. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 83 (2008) 68-76
43. Lennestal R., and Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 27 (2007) 607-613
44. Chambers C., et al. Selective serotonin-reuptake inhibitors and risk of persisitent pulmonary hypertension of the newborn. N Engl J Med 354 (2006) 579-587
45. Oberlander T., et al. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 13 (2008) 65-73
46. Laine K., Heikkinen T., Ekblad U., and Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 60 (2003) 720-726
47. Oberlander T., et al. Pharmacologic factors associated with transient neonatal symptoms following prental psychotropic medication exposure. J Clin Psychiatry 65 (2004) 230-237
48. Zeskind P., and Stephens L. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics. 113 (2004) 368-375
49. Källén B., and Olausson P. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 17 (2008) 801-806
50. Greenough A., and Khetriwal B. Pulmonary hypertension in the newborn. Paediatr Respir Rev. 6 (2005) 111-116
51. Nulman I., et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336 (1997) 258-262
52. Nulman I., et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 159 (2002) 1889-1895
53. Miller L. Use of electroconvulsive therapy during pregnancy. Hosp Commun Psychiatry 45 5 (1994) 444-450
54. Cox J., and Holden J. Perinatal psychiatry. Use and misuse of the Edinburgh Postnatal Depression Scale (1994), The Royal College of Psychiatrists, Glasgow
55. Matthey S., Henshaw C., Elliott S., and Barnett B. Variability in use of cut-off scores and formats on the Edinburgh Postnatal Depression Scale: implications for clinical and research practice. Arch Women Ment Health 9 (2006) 309-315
56. Spitzer R., Williams J., Kroenke K., Hornyak R., and McMurray J. Validity and utility of the Patient Health Questionnaire (PHQ) in assessing 3000 obstetric gynecology patients: The Prime-MD PHQ obstetric gynecology study. Am J Obstet Gynecol 183 3 (2000) 759-769
57. Spinelli M., and Endicott J. Controlled clinical trial of interpersonal psychotherapy versus parenting education program for depressed pregnant women. Am J Psychiatry 160 (2003) 555-562
58. Altshuler L.L., et al. The Expert Consensus Guideline Series. Treatment of depression in women. Postgrad. Med. (2001) 1-107
59. Wisner K., Gelenberg A., Leonard H., Zarin D., and Frank E. Pharmacologic treatment of depression during pregnancy. JAMA 282 (1999) 1264-1269
60. Yonkers K., et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 161 (2004) 608-620
61. Finer L., and Henshaw S. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 38 (2006) 90-96
62. Rush A., et al. Depression in primary care: Vol. 2. Treatment of Major Depression. Clinical Practice Guideline Number. 5th ed. (1993), Agency for Health Care Policy and Research, Rockville, MD
63. Wisner K., Perel J., and Wheeler S. Tricyclic dose requirements across pregnancy. Am J Psychiatry 150 10 (1993) 1541-1542
64. Cohen L., et al. Relapse of major depressive during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295 (2006) 499-507